<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010045.anc" start="423" end="430" sStart="252" offset="171" sid="r8.suggest.v.0893" wn="3" wnkey="suggest%2:32:02::" annotator="veweser" text="Many individuals suffer simultaneously from more than one of these conditions, and epidemiological studies in humans, as well as studies in animal models, suggest that obesity-related insulin resistance is a common pathogenic feature [2]." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010045.anc" start="2401" end="2410" sStart="null" offset="31" sid="r8.suggest.v.0621" wn="3" wnkey="suggest%2:32:02::" annotator="veweser" text="Recently, several studies have suggested that metabolic abnormalities are associated with polymorphisms in the human resistin gene [17,18]." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010045.anc" start="21925" end="21931" sStart="null" offset="25" sid="r11.strong.j.0202" wn="1" wnkey="strong%3:00:00::" annotator="vebatchelder" text="Intriguingly, we found a strong correlation between plasma levels of resistin and sTNFR2, the soluble cleavage product of the activated TNF? receptor, in diabetic patients." />
    <s path="file:/c:/OANC/data/written_2/technical/plos/pmed.0010045.anc" start="17861" end="17866" sStart="null" offset="0" sid="null" wn="2" wnkey="show%2:31:00::" annotator="carichter" text="Six healthy volunteers were injected with LPS, using a protocol similar to that &lt;b&gt;shown&lt;/b&gt; to produce insulin resistance [35]." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010045.anc" start="6397" end="6402" sStart="null" offset="273" sid="r9.sense.n.0901" wn="2147483646" wnkey="null" annotator="veweser" text="The primers and probes used in the real-time PCR were the following: Sense-Resistin, 5?- AGCCATCAATGATAGGATCCA-3?; Antisense-Resistin, 5?- TCCAGGCCAATGCTGCTTAT-3?; Resistin Probe, 5?-Fam- AGGTCGCCGGCTCCCTAATATTTAGGG-TAMRA-3?; Sense human 36B4 sense, 5?- TCGTGGAAGTGACATCGTCTTT-3?; Antisense 36B4, 5?- CTGTCTTCCCTGGGCATCA-3?; and 36B4 Probe, 5?-FAM- TGGCAATCCCTGACGCACCG-TAMRA-3?." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010045.anc" start="6380" end="6385" sStart="null" offset="256" sid="r9.sense.n.0966" wn="0" wnkey="null" annotator="anfahmy" text="The primers and probes used in the real-time PCR were the following: Sense-Resistin, 5?- AGCCATCAATGATAGGATCCA-3?; Antisense-Resistin, 5?- TCCAGGCCAATGCTGCTTAT-3?; Resistin Probe, 5?-Fam- AGGTCGCCGGCTCCCTAATATTTAGGG-TAMRA-3?; Sense human 36B4 sense, 5?- TCGTGGAAGTGACATCGTCTTT-3?; Antisense 36B4, 5?- CTGTCTTCCCTGGGCATCA-3?; and 36B4 Probe, 5?-FAM- TGGCAATCCCTGACGCACCG-TAMRA-3?." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010045.anc" start="3446" end="3452" sStart="null" offset="15" sid="r9.level.n.0888" wn="2" wnkey="level%1:26:01::" annotator="brubin" text="Resistin serum levels are increased dramatically by endotoxemia in humans, and correlate with a marker of inflammation in patients with type 2 diabetes." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010045.anc" start="19340" end="19346" sStart="null" offset="57" sid="r9.level.n.0898" wn="1" wnkey="level%1:07:00::" annotator="anfahmy" text="Thus, there is an association between resistin levels and systemic inflammation in patients with type 2 diabetes." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010045.anc" start="1704" end="1709" sStart="null" offset="102" sid="r8.1.great.j.0635" wn="1" wnkey="great%5:00:01:large:00" annotator="brubin" text="Hence, the interrelationships between obesity, insulin resistance, and atherosclerosis are of great scientific and clinical interest." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010045.anc" start="6818" end="6822" sStart="null" offset="4" sid="r9.fold.v.0388" wn="2147483645" wnkey="null" annotator="brubin" text="The fold change in expression of the gene of interest in the compound-treated group relative to that in the vehicle-treated group was expressed as 2 ?deltadeltaCT , in which deltadeltaCT equals the deltaCT of the compound-treated group minus the deltaCT of the chosen control group, which was normalized to 1." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010045.anc" start="5440" end="5444" sStart="null" offset="53" sid="r7.1.easy.j.0792" wn="2147483644" wnkey="null" annotator="cgozo" text="Adenovirus expressing activated IKK in pAD easy with GFP and control vector was a generous gift from Steven Shoelson." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010045.anc" start="5458" end="5465" sStart="null" offset="71" sid="r10.control.n.0880" wn="4" wnkey="control%1:09:02::" annotator="brubin" text="Adenovirus expressing activated IKK in pAD easy with GFP and control vector was a generous gift from Steven Shoelson." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010045.anc" start="5342" end="5349" sStart="null" offset="76" sid="r10.control.n.0452" wn="4" wnkey="control%1:09:02::" annotator="brubin" text="Neutralizing antibodies to TNF?, IL-6, and anti-IL-1?, as well as control IgG, were obtained from R&amp;D Systems." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010045.anc" start="14681" end="14692" sStart="null" offset="13" sid="r11.combination.n.0937" wn="1" wnkey="combination%1:14:00::" annotator="vebatchelder" text="However, the combination of antibodies to TNF?, IL-6, and IL-1? markedly attenuated LPS induction of resistin (Figure 3C)." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0010045.anc" start="8872" end="8877" sStart="null" offset="62" sid="r10.board.n.0360" wn="1" wnkey="board%1:14:00::" annotator="brubin" text="The University of Pennsylvania Institutional Review Board approved the study protocol, and all participants gave written informed consent." />
  </sentences>
</list>